---All---
  • ---All---
  • Accession
  • Catalog #

APG8c (MAP1LC3C) Antibody (Y105) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP1804f 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

APG8c (MAP1LC3C) Antibody (Y105) Blocking Peptide - Product info

Primary AccessionQ9BXW4
Clone Names80317114
Calculated MW16852 Da

APG8c (MAP1LC3C) Antibody (Y105) Blocking Peptide - Additional info

Gene ID 440738
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1804f was selected from the MAP1LC3C region of human APG8c (MAP1LC3C). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APG8c (MAP1LC3C) Antibody (Y105) Blocking Peptide - Protein Information

Name MAP1LC3C
Function
Probably involved in formation of autophagosomal vacuoles (autophagosomes) (By similarity)
Cellular Location
Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Note=LC3-II binds to the autophagic membranes
Tissue Location
Most abundant in placenta, lung and ovary.

APG8c (MAP1LC3C) Antibody (Y105) Blocking Peptide - Related products

AP1804a: LC3 Antibody (APG8C) (N-term)

AP1804e: LC3 Antibody (APG8C) (T48)

AP1804f: LC3 Antibody (APG8C) (Y105)

AP3457a: Phospho-LC3C-S9 Antibody

AP3531a: Phospho-LC3C-S137/138 Antibody

AP3646a: Phospho-LC3C-T48 Antibody

AP3691a: Phospho-APG8c (MAP1LC3C)-Y105 Antibody

RI13152: MAP1LC3C predesign siRNA

BP1804a: LC3 Antibody (APG8c) (N-term) Blocking Peptide

BP1804e: APG8c (MAP1LC3C) Antibody (T48) Blocking Peptide

BP1804f: APG8c (MAP1LC3C) Antibody (Y105) Blocking Peptide

BP3457a: Phospho-LC3 (APG8c) - S9 Antibody Blocking Peptide

BP3531a: Phospho-LC3 (APG8c) - S137/138 Antibody Blocking Peptide

BP3646a: Phospho-APG8c (MAP1LC3C)-T48 Antibody Blocking Peptide

BP3647a: Phospho-APG8c (MAP1LC3C)-Y105 Antibody Blocking Peptide

BP3691a: Phospho-APG8c (MAP1LC3C)-Y105 Antibody Blocking Peptide

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3c is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.

REFERENCES

Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004)He H., et al. J. Biol. Chem. 278:29278-29287(2003)Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)